Side-by-side comparison of AI visibility scores, market position, and capabilities
Indoor vertical farming company using AI-optimized growing systems. San Francisco, CA. Raised $940M+ including $400M from SoftBank. Partners with Walmart for US farms.
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has raised over $940 million from investors including SoftBank Vision Fund, which invested $200 million in 2017, and has positioned itself as the technology leader in data-driven indoor agriculture.\n\nPlenty's farms use precisely controlled light, temperature, humidity, and nutrient conditions to grow crops that are free from pesticides, use 99% less land, and consume significantly less water than conventional field agriculture. The company's AI systems continuously optimize growing conditions based on sensor data, learning to improve yields and quality across crops and growing cycles.\n\nIn 2022, Plenty announced a landmark partnership with Walmart to supply leafy greens from a new large-scale facility in Compton, California. This partnership provided both a major commercial anchor and significant additional funding from Walmart, validating Plenty's technology and business model at scale. The company also operates a dedicated strawberry R&D partnership with Driscoll's, the world's largest berry company, demonstrating the platform's potential beyond leafy greens.
Emerged from stealth with $100M (Dec 2025) backed by Gates Foundation, SR One, Abingworth. PRINT LNP platform integrates RNA at specific genomic loci — potentially re-dosable gene therapy for rare and chronic diseases.
Addition Therapeutics emerged from stealth in December 2025 with $100 million in financing backed by the Gates Foundation, SR One, and Abingworth, developing PRINT — a platform using lipid nanoparticles (LNPs) to deliver RNA and enzyme payloads that integrate therapeutic sequences at specific genomic loci. Unlike traditional AAV gene therapy (which requires viral vectors and can only be dosed once due to immune response), PRINT's non-viral approach is potentially re-dosable, opening gene therapy to chronic diseases beyond rare genetic disorders.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.